vs

Side-by-side financial comparison of Red Cat Holdings, Inc. (RCAT) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.

Red Cat Holdings, Inc. is the larger business by last-quarter revenue ($9.6M vs $5.5M, roughly 1.8× Taysha Gene Therapies, Inc.). Red Cat Holdings, Inc. runs the higher net margin — -166.0% vs -507.8%, a 341.7% gap on every dollar of revenue. On growth, Red Cat Holdings, Inc. posted the faster year-over-year revenue change (988.2% vs 171.3%).

Mega Cat Studios is an American video game development and publishing company located in Pittsburgh, Pennsylvania. It was founded in 2015 by James Deighan, Nick Mann, and Zack Manko.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.

RCAT vs TSHA — Head-to-Head

Bigger by revenue
RCAT
RCAT
1.8× larger
RCAT
$9.6M
$5.5M
TSHA
Growing faster (revenue YoY)
RCAT
RCAT
+817.0% gap
RCAT
988.2%
171.3%
TSHA
Higher net margin
RCAT
RCAT
341.7% more per $
RCAT
-166.0%
-507.8%
TSHA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
RCAT
RCAT
TSHA
TSHA
Revenue
$9.6M
$5.5M
Net Profit
$-16.0M
$-27.9M
Gross Margin
6.6%
Operating Margin
-181.7%
-516.0%
Net Margin
-166.0%
-507.8%
Revenue YoY
988.2%
171.3%
Net Profit YoY
-29.0%
-48.3%
EPS (diluted)
$-0.16
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RCAT
RCAT
TSHA
TSHA
Q4 25
$5.5M
Q3 25
$9.6M
$0
Q2 25
$2.0M
Q1 25
$1.6M
$2.3M
Q4 24
$0
$2.0M
Q3 24
$1.8M
Q2 24
$1.1M
Q1 24
$5.8M
$3.4M
Net Profit
RCAT
RCAT
TSHA
TSHA
Q4 25
$-27.9M
Q3 25
$-16.0M
$-32.7M
Q2 25
$-26.9M
Q1 25
$-23.1M
$-21.5M
Q4 24
$-13.3M
$-18.8M
Q3 24
$-25.5M
Q2 24
$-20.9M
Q1 24
$-5.5M
$-24.1M
Gross Margin
RCAT
RCAT
TSHA
TSHA
Q4 25
Q3 25
6.6%
Q2 25
Q1 25
-52.2%
Q4 24
Q3 24
Q2 24
Q1 24
18.8%
Operating Margin
RCAT
RCAT
TSHA
TSHA
Q4 25
-516.0%
Q3 25
-181.7%
Q2 25
-1347.1%
Q1 25
-765.7%
-930.5%
Q4 24
-985.8%
Q3 24
-1448.4%
Q2 24
-1915.4%
Q1 24
-76.0%
-713.3%
Net Margin
RCAT
RCAT
TSHA
TSHA
Q4 25
-507.8%
Q3 25
-166.0%
Q2 25
-1353.6%
Q1 25
-1418.9%
-935.2%
Q4 24
-929.0%
Q3 24
-1427.5%
Q2 24
-1882.0%
Q1 24
-93.9%
-705.4%
EPS (diluted)
RCAT
RCAT
TSHA
TSHA
Q4 25
$-0.08
Q3 25
$-0.16
$-0.09
Q2 25
$-0.09
Q1 25
$-0.27
$-0.08
Q4 24
$-0.07
Q3 24
$-0.10
Q2 24
$-0.09
Q1 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RCAT
RCAT
TSHA
TSHA
Cash + ST InvestmentsLiquidity on hand
$319.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$253.3M
$246.9M
Total Assets
$286.0M
$343.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RCAT
RCAT
TSHA
TSHA
Q4 25
$319.8M
Q3 25
$297.3M
Q2 25
$312.8M
Q1 25
$116.6M
Q4 24
$139.0M
Q3 24
$157.7M
Q2 24
$172.7M
Q1 24
$124.0M
Stockholders' Equity
RCAT
RCAT
TSHA
TSHA
Q4 25
$246.9M
Q3 25
$253.3M
$219.0M
Q2 25
$248.7M
Q1 25
$28.9M
$55.1M
Q4 24
$27.0M
$71.5M
Q3 24
$88.8M
Q2 24
$108.9M
Q1 24
$49.6M
$53.8M
Total Assets
RCAT
RCAT
TSHA
TSHA
Q4 25
$343.3M
Q3 25
$286.0M
$316.6M
Q2 25
$333.3M
Q1 25
$59.7M
$138.4M
Q4 24
$51.1M
$160.4M
Q3 24
$180.2M
Q2 24
$200.4M
Q1 24
$55.3M
$153.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RCAT
RCAT
TSHA
TSHA
Operating Cash FlowLast quarter
$-23.9M
$-26.7M
Free Cash FlowOCF − Capex
$-24.5M
FCF MarginFCF / Revenue
-254.2%
Capex IntensityCapex / Revenue
6.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-55.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RCAT
RCAT
TSHA
TSHA
Q4 25
$-26.7M
Q3 25
$-23.9M
$-24.2M
Q2 25
$-20.2M
Q1 25
$-15.9M
$-22.0M
Q4 24
$-10.1M
$-18.3M
Q3 24
$-21.6M
Q2 24
$-21.5M
Q1 24
$-4.1M
$-19.8M
Free Cash Flow
RCAT
RCAT
TSHA
TSHA
Q4 25
Q3 25
$-24.5M
$-24.3M
Q2 25
Q1 25
$-16.2M
Q4 24
$-10.2M
$-18.3M
Q3 24
$-21.6M
Q2 24
$-21.7M
Q1 24
$-4.2M
$-19.9M
FCF Margin
RCAT
RCAT
TSHA
TSHA
Q4 25
Q3 25
-254.2%
Q2 25
Q1 25
-992.9%
Q4 24
-905.5%
Q3 24
-1210.9%
Q2 24
-1951.9%
Q1 24
-71.1%
-584.5%
Capex Intensity
RCAT
RCAT
TSHA
TSHA
Q4 25
Q3 25
6.9%
Q2 25
Q1 25
16.8%
Q4 24
0.1%
Q3 24
2.0%
Q2 24
18.1%
Q1 24
0.8%
4.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RCAT
RCAT

Products$8.5M88%
Services$1.2M12%

TSHA
TSHA

Segment breakdown not available.

Related Comparisons